These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9427148)

  • 1. Aspartylglucosaminuria among Palestinian Arabs.
    Zlotogora J; Ben-Neriah Z; Abu-Libdeh BY; Sury V; Zeigler M
    J Inherit Metab Dis; 1997 Nov; 20(6):799-802. PubMed ID: 9427148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectrum of mutations in aspartylglucosaminuria.
    Ikonen E; Aula P; Grön K; Tollersrud O; Halila R; Manninen T; Syvänen AC; Peltonen L
    Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11222-6. PubMed ID: 1722323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspartylglycosaminuria: a review.
    Arvio M; Mononen I
    Orphanet J Rare Dis; 2016 Dec; 11(1):162. PubMed ID: 27906067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissection of the molecular pathology of aspartylglucosaminuria provides the basis for DNA diagnostics and future therapeutic interventions.
    Ikonen E; Syvänen AC; Peltonen L
    Scand J Clin Lab Invest Suppl; 1993; 213():19-27. PubMed ID: 8322015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convenient and quantitative determination of the frequency of a mutant allele using solid-phase minisequencing: application to aspartylglucosaminuria in Finland.
    Syvänen AC; Ikonen E; Manninen T; Bengtström M; Söderlund H; Aula P; Peltonen L
    Genomics; 1992 Mar; 12(3):590-5. PubMed ID: 1559710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel mutation causing aspartylglucosaminuria reveals a mutation hotspot region in the aspartylglucosaminidase gene.
    Isoniemi A; Hietala M; Aula P; Jalanko A; Peltonen L
    Hum Mutat; 1995; 5(4):318-26. PubMed ID: 7627186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overgrowth of oral mucosa and facial skin, a novel feature of aspartylglucosaminuria.
    Arvio P; Arvio M; Kero M; Pirinen S; Lukinmaa PL
    J Med Genet; 1999 May; 36(5):398-404. PubMed ID: 10353787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mice with an aspartylglucosaminuria mutation similar to humans replicate the pathophysiology in patients.
    Jalanko A; Tenhunen K; McKinney CE; LaMarca ME; Rapola J; Autti T; Joensuu R; Manninen T; Sipilä I; Ikonen S; Riekkinen P; Ginns EI; Peltonen L
    Hum Mol Genet; 1998 Feb; 7(2):265-72. PubMed ID: 9425233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two novel mutations in a Canadian family with aspartylglucosaminuria and early outcome post bone marrow transplantation.
    Laitinen A; Hietala M; Haworth JC; Schroeder ML; Seargeant LE; Greenberg CR; Aula P
    Clin Genet; 1997 Mar; 51(3):174-8. PubMed ID: 9137882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations causing aspartylglucosaminuria (AGU): a lysosomal accumulation disease.
    Ikonen E; Peltonen L
    Hum Mutat; 1992; 1(5):361-5. PubMed ID: 1301945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspartylglucosaminuria in northern Norway: a molecular and genealogical study.
    Tollersrud OK; Nilssen O; Tranebjaerg L; Borud O
    J Med Genet; 1994 May; 31(5):360-3. PubMed ID: 8064811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular analysis of the aspartylglucosaminidase gene in Japanese patients with aspartylglucosaminuria].
    Yoshida K
    Nihon Rinsho; 1993 Sep; 51(9):2308-13. PubMed ID: 8411707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic arthritis in patients with aspartylglucosaminuria.
    Arvio MA; Rapola JM; Pelkonen PM
    J Rheumatol; 1998 Jun; 25(6):1131-4. PubMed ID: 9632076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspartylglucosaminuria in a Puerto Rican family: additional features of a panethnic disorder.
    Chitayat D; Nakagawa S; Marion RW; Sachs GS; Hahm SY; Goldman HS
    Am J Med Genet; 1988 Nov; 31(3):527-32. PubMed ID: 3228136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction of deficient enzyme activity in a lysosomal storage disease, aspartylglucosaminuria, by enzyme replacement and retroviral gene transfer.
    Enomaa N; Danos O; Peltonen L; Jalanko A
    Hum Gene Ther; 1995 Jun; 6(6):723-31. PubMed ID: 7548272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Origin of Finnish mutations causing aspartylglucosaminuria.
    Valkonen S; Hietala M; Savontaus ML; Aula P
    Hereditas; 1999; 131(3):191-5. PubMed ID: 10783529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspartylglucosaminuria caused by a novel homozygous mutation in the AGA gene was identified by an exome-first approach in a patient from Japan.
    Yamamoto T; Shimojima K; Matsufuji M; Mashima R; Sakai E; Okuyama T
    Brain Dev; 2017 May; 39(5):422-425. PubMed ID: 28063748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human aspartylglucosaminidase. A biochemical and immunocytochemical characterization of the enzyme in normal and aspartylglucosaminuria fibroblasts.
    Enomaa N; Heiskanen T; Halila R; Sormunen R; Seppälä R; Vihinen M; Peltonen L
    Biochem J; 1992 Sep; 286 ( Pt 2)(Pt 2):613-8. PubMed ID: 1530592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse.
    Peltola M; Kyttälä A; Heinonen O; Rapola J; Paunio T; Revah F; Peltonen L; Jalanko A
    Gene Ther; 1998 Oct; 5(10):1314-21. PubMed ID: 9930336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction of peripheral lysosomal accumulation in mice with aspartylglucosaminuria by bone marrow transplantation.
    Laine M; Richter J; Fahlman C; Rapola J; Renlund M; Peltonen L; Karlsson S; Jalanko A
    Exp Hematol; 1999 Sep; 27(9):1467-74. PubMed ID: 10480438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.